Our findings may therefore help to elucidate several unexpected observations in clinical cancer samples and propose an alternative context-specific role of MDM2 in EMT, tumor progression, and sensitivity to chemotherapy in cells with defective p53 function. This evidence concerns the gene TP53 and cancer.